Immunology of combining CRM197 conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants

Vaccine

Volumn 27, Issue 17, 2009, Pages 2299-2305

  Lagos, Rosanna ^a,b   Munoz, Alma ^b   Levine, Myron M ^c   Watson, Wendy ^d   Chang, Ih ^e   Paradiso, Peter ^f  

^a HOSPITAL ROBERTO DEL RÍO   (Chile)

^b Centro para Vacunas en Desarrollo Chile   (Chile)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d WYETH RESEARCH   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f PFIZER INC   (United States)

Author keywords

Combination vaccines; Immunogenicity; Pneumococcal conjugate vaccine

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID CRM197; DIPHTHERIA TOXOID CRM197 HAEMOPHILUS INFLUENZAE TYPE B NONAVALENT PNEUMOCOCCUS MENINGOCOCCUS CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE; NONAVALENT PNEUMOCOCCUS MENINGOCOCCUS CONJUGATE VACCINE; NONAVALENT PNEUMOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; APPETITE; CHILE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG CONJUGATION; DRUG FORMULATION; DRUG MIXTURE; DRUG SAFETY; FEVER; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; IRRITABILITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE BLIND PROCEDURE; STREPTOCOCCUS PNEUMONIAE;

ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL PROTEINS; CHILE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL VACCINES; SINGLE-BLIND METHOD; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 62249193542     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.022     Document Type: Review

References (23)

1. World Health Organization. Global immunization vision and strategy. April 2005. Available at: www.who.int/vaccines/GIVS/english/Global_imm._data_EN.pdf.
2. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 (2000) 187-195
3. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 (2002) 810-815
4. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344 (2001) 403-409
5. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., and Pierce N. Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 (2003) 1341-1348
6. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Gambian Pneumococcal Vaccine Trial Group Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 (2005) 1139-1146
7. World Health Organization. WHO Technical Report Series: recommendations for the production and control of pneumococcal conjugate vaccines, No. 927. 2005; pp 66-98.
8. Quataert S.A., Kirch C.S., Wiedl L.J., Phipps D.C., Strohmeyer S., Cimino C.D., et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 2 (1995) 590-597
9. Phipps D.C., West J., Eby R., Koster M., Madore D.V., and Quataert S.A. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 135 (1990) 121-128
10. Madore D.V., Anderson P., Baxter B.D., Carlone G.M., Edwards K.M., Hamilton R.G., et al. Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 3 (1996) 84-88
11. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitides serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4 (1997) 156-167
12. Huebner R.E., Mbelle N., Forrest B., Madorre D.V., and Klugman K.P. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal vaccine in infants in Soweto, South Africa. Pediatr Infect Dis J 21 (2002) 1004-1007
13. Rennels M.B., Edwards K.M., Keyserling H.L., Reisinger K.S., Hogerman D.A., Madore D.V., et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101 4 Pt 1 (1998) 604-611
14. Dagan R., Poolman J.T., and Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines 7 (2008) 97-115
15. Dagan R., Eskola J., Leclerc C., and Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 (1998) 2093-2098
16. Dagan R., Goldblatt D., Maleckar J.R., Yaïch M., and Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 72 (2004) 5383-5391
17. Pichichero M.E., Latiolais T., Bernstein D.I., Hosbach P., Christian E., Vidor E., et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. Pediatr Infect Dis J 16 (1997) 863-870
18. Rennels M.B., Hohenboken M.J., Reisinger K.S., Clements D.A., Walter Jr. E.B., Blatter M.M., et al. Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately vs. combined in younger vs. older toddlers. Pediatr Infect Dis J 17 (1998) 164-166
19. Fattom A., Cho Y.H., Chu C., Fuller S., Fries L., and Naso R. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17 (1999) 126-133
20. Peeters C.C., Tenbergen-Meekes A.M., Poolman J.T., Beurret M., Zegers B.J., and Rijkers G.T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 59 (1991) 3504-3510
21. Daum R.S., Hogerman D., Rennels M.B., Bewley K., Malinoski F., Rothstein E., et al. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 176 (1997) 445-455
22. Bryant KA, Block SL, Scott DA. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Presented at the 25th ESPID; May 4, 2007; Porto, Portugal.
23. McVernon J., Andrews N., Slack M.P., and Ramsay M.E. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361 (2003) 1521-1523